FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600382672> ?p ?o ?g. }

• W2600382672 abstract "Abstract Abstract 3048 Acute graft-versus-host disease (aGvHD) of the gastrointestinal (GI) tract is still a major clinical challenge after allogeneic stem cell transplantation. Patients with steroid-refractory disease have a poor prognosis. Pentostatin, an inhibitor of adenosine deaminase, has shown efficacy as salvage therapy in steroid-refractory aGvHD of the GI tract in small single center studies. Here we report on the experience with pentostatin in severe steroid-refractory aGvHD of the GI tract at seven German transplant centers. PATIENTS: A total number of 123 patients who had been treated with pentostatin due to intestinal steroid-refractory aGvHD between 2000 and 2011 were retrospectively analyzed. Steroid-refractory aGvHD was defined as progression or no improvement of diarrhea despite treatment with prednisolone (≥ 2mg/kg/d) for ≥ 3 days. Pentostatin was infused at a dose of 1mg/m2 for 3 consecutive days. In patients with impaired renal function the dose of pentostatin was reduced. Patients received 1–4 cycles. Steroids and calcineurin inhibitors (CNI) were continued. Response after therapy with pentostatin was classified as complete (CR, no ongoing symptoms of GvHD), very good partial (VGPR, residual symptoms only) or no response (NR). 50 females and 73 males with a median age of 50 (range: 19–70) years were included. The underlying diseases were AML (n=71), ALL (n=15), CML/MPS (n=6), lymphoma (n=12), MDS (n=10), and multiple myeloma (n=9). 85 patients received reduced intensity and 38 myeloablative conditioning. Patients had been transplanted from matched related (n=38), matched unrelated (n=53) or mismatched donors (n=32). All patients suffered from severe steroid-refractory intestinal aGvHD overall grade III (n=59) or IV (n=64). Patients received pentostatin as first line salvage (n=109) or beyond first line salvage therapy (n=14). Results: 52 patients (43%) responded after salvage therapy with pentostatin. 39 patients (32%) achieved CR, 13 patients (11%) VGPR. Median survival was 104 days; 2-year and long term survival rates were 26 and 19% with a median follow up of 45 months. Among 109 patients who received pentostatin as first line salvage therapy 49 (45%) responded (37 × CR [34%] and 12 × VGPR [11%]). Median survival, 2-year and long term survival were essentially the same as in the total cohort of patients. After the first infusion of pentostatin clinical improvement occurred within a median of 14 (range: 1–58) days. 71 patients (57%) did not respond. Responding patients had a significantly (p<0.0001) higher probability of survival in comparison with non-responders (2 year survival 44 vs. 14%, long term survival 41 vs. 0%). 94 patients (76%) died (66% therapy related, 10% due to relapse of the malignant disease). Patients who had been transplanted from a matched related donor had a significantly (p=0.04) higher probability of survival in comparison with patients with other donors (2-year survival: 38 vs. 21%, long term survival 35 vs. 8%). 53% (n=20) of these patients responded. Out of the 109 patients who were treated with pentostatin as first line salvage therapy 15 received simultaneously additional immunsuppressive salvage therapies (infliximab, mesenchymal stem cells [MSC] or extracorporeal photopheresis [ECP]). None of these patients survived. 46 patients without CR after one cycle of pentostatin received further immunosuppressive salvage treatment: 28 of these patients were treated with 1–3 further cycles of pentostatin. 18 of the 46 patients received pentostatin plus simultaneous or subsequent additional immunsuppressive therapies (infliximab, alemtuzumab, basiliximab, MSC or ECP). In both groups the probability of survival was identical (2-year survival: 17%). Conclusions: The outcome after salvage therapy of III/IV° steroid-refractory intestinal aGvHD with pentostatin is at least within the range as reported for other salvage approaches. In this critical clinical situation pentostatin has some superior characteristics: a sustainable effect, moderate toxicity, easy application and cost-effectiveness. Moreover, this analysis suggests that the outcome of steroid-refractory aGvHD cannot be improved by the application of more than one immunosuppressive salvage drug in addition to steroids and CNI or by second line salvage approaches. Disclosures: Klein: Hospira: Honoraria, Research Funding. Off Label Use: pentostatin is not licensed for use in acute GvHD." @default.
• W2600382672 created "2017-04-07" @default.
• W2600382672 creator A5004741011 @default.
• W2600382672 creator A5014745384 @default.
• W2600382672 creator A5026579243 @default.
• W2600382672 creator A5029332875 @default.
• W2600382672 creator A5042854645 @default.
• W2600382672 creator A5046718799 @default.
• W2600382672 creator A5053168954 @default.
• W2600382672 creator A5054393582 @default.
• W2600382672 creator A5078512688 @default.
• W2600382672 creator A5085146093 @default.
• W2600382672 creator A5087237103 @default.
• W2600382672 creator A5090795046 @default.
• W2600382672 date "2011-11-18" @default.
• W2600382672 modified "2023-09-27" @default.
• W2600382672 title "A Multicenter Retrospective Analysis on Pentostatin As Salvage Therapy of Severe Steroid Refractory Intestinal Acute Graft Versus Host Disease" @default.
• W2600382672 doi "https://doi.org/10.1182/blood.v118.21.3048.3048" @default.
• W2600382672 hasPublicationYear "2011" @default.
• W2600382672 type Work @default.
• W2600382672 sameAs 2600382672 @default.
• W2600382672 citedByCount "0" @default.
• W2600382672 crossrefType "journal-article" @default.
• W2600382672 hasAuthorship W2600382672A5004741011 @default.
• W2600382672 hasAuthorship W2600382672A5014745384 @default.
• W2600382672 hasAuthorship W2600382672A5026579243 @default.
• W2600382672 hasAuthorship W2600382672A5029332875 @default.
• W2600382672 hasAuthorship W2600382672A5042854645 @default.
• W2600382672 hasAuthorship W2600382672A5046718799 @default.
• W2600382672 hasAuthorship W2600382672A5053168954 @default.
• W2600382672 hasAuthorship W2600382672A5054393582 @default.
• W2600382672 hasAuthorship W2600382672A5078512688 @default.
• W2600382672 hasAuthorship W2600382672A5085146093 @default.
• W2600382672 hasAuthorship W2600382672A5087237103 @default.
• W2600382672 hasAuthorship W2600382672A5090795046 @default.
• W2600382672 hasConcept C121332964 @default.
• W2600382672 hasConcept C126322002 @default.
• W2600382672 hasConcept C141071460 @default.
• W2600382672 hasConcept C142424586 @default.
• W2600382672 hasConcept C2775952470 @default.
• W2600382672 hasConcept C2776694085 @default.
• W2600382672 hasConcept C2777408962 @default.
• W2600382672 hasConcept C2779338263 @default.
• W2600382672 hasConcept C2779972918 @default.
• W2600382672 hasConcept C2780653079 @default.
• W2600382672 hasConcept C2780775027 @default.
• W2600382672 hasConcept C2911091166 @default.
• W2600382672 hasConcept C71924100 @default.
• W2600382672 hasConcept C87355193 @default.
• W2600382672 hasConcept C90924648 @default.
• W2600382672 hasConceptScore W2600382672C121332964 @default.
• W2600382672 hasConceptScore W2600382672C126322002 @default.
• W2600382672 hasConceptScore W2600382672C141071460 @default.
• W2600382672 hasConceptScore W2600382672C142424586 @default.
• W2600382672 hasConceptScore W2600382672C2775952470 @default.
• W2600382672 hasConceptScore W2600382672C2776694085 @default.
• W2600382672 hasConceptScore W2600382672C2777408962 @default.
• W2600382672 hasConceptScore W2600382672C2779338263 @default.
• W2600382672 hasConceptScore W2600382672C2779972918 @default.
• W2600382672 hasConceptScore W2600382672C2780653079 @default.
• W2600382672 hasConceptScore W2600382672C2780775027 @default.
• W2600382672 hasConceptScore W2600382672C2911091166 @default.
• W2600382672 hasConceptScore W2600382672C71924100 @default.
• W2600382672 hasConceptScore W2600382672C87355193 @default.
• W2600382672 hasConceptScore W2600382672C90924648 @default.
• W2600382672 hasLocation W26003826721 @default.
• W2600382672 hasOpenAccess W2600382672 @default.
• W2600382672 hasPrimaryLocation W26003826721 @default.
• W2600382672 hasRelatedWork W2043711686 @default.
• W2600382672 hasRelatedWork W2176372514 @default.
• W2600382672 hasRelatedWork W2512482749 @default.
• W2600382672 hasRelatedWork W2552472544 @default.
• W2600382672 hasRelatedWork W2554179504 @default.
• W2600382672 hasRelatedWork W2556870097 @default.
• W2600382672 hasRelatedWork W2560761344 @default.
• W2600382672 hasRelatedWork W2561840255 @default.
• W2600382672 hasRelatedWork W2564899959 @default.
• W2600382672 hasRelatedWork W2587791009 @default.
• W2600382672 hasRelatedWork W2587833499 @default.
• W2600382672 hasRelatedWork W2596951162 @default.
• W2600382672 hasRelatedWork W2597016111 @default.
• W2600382672 hasRelatedWork W2598453051 @default.
• W2600382672 hasRelatedWork W2900583202 @default.
• W2600382672 hasRelatedWork W2993647347 @default.
• W2600382672 hasRelatedWork W3001340283 @default.
• W2600382672 hasRelatedWork W3026642736 @default.
• W2600382672 hasRelatedWork W3096342995 @default.
• W2600382672 hasRelatedWork W2466978759 @default.
• W2600382672 isParatext "false" @default.
• W2600382672 isRetracted "false" @default.
• W2600382672 magId "2600382672" @default.
• W2600382672 workType "article" @default.